Rocket Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary

Rocket Pharmaceuticals

13/08/2026 13:00

Rocket Pharmaceuticals, Inc. RCKT.OQ reported a quarterly adjusted loss of 48 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -59 cents.  The mean expectation of thirteen analysts for the quarter was for earnings of 24 cents per share. Wall Street expected results to range from -54 cents to $1.17 per share.
Reported revenue was zero​; analysts expected $20.00 million. 
Rocket Pharmaceuticals, Inc.'s reported EPS for the quarter was $1.08​.
The company reported quarterly net income of $123.21 million.
Rocket Pharmaceuticals, Inc. shares had fallen by 0.3% this quarter and lost 2.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 18.6% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy," 6 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for Rocket Pharmaceuticals, Inc. is $8.50, about 59.9% above its last closing price of $3.41
This summary was machine generated from LSEG data August 13 at 11:59 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.24
-0.48
Missed
Mar. 31 2026 
-0.41
-0.42
Missed
Dec. 31 2025 
-0.45
-0.38
Beat
Sep. 30 2025 
-0.50
-0.45
Beat